Regeneron Grows 36%, Gilead Spends About USD 12.7 Billion on Four Deals and Pharma Buyers Race to Refill Pipelines: Precedence Research Company Intelligence on Leaders, Investments and Developments

Ottawa, Nov. 17, 2026 (GLOBE NEWSWIRE) --

The global biotechnology market is valued at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a CAGR of 13.61%. Leading biotech companies raised their 2026 outlooks after third-quarter results, while large drugmakers announced acquisitions and collaborations worth tens of billions of dollars.

Precedence Research today released updated company intelligence on the global biotechnology market, focusing on the companies that lead it and the investments and developments shaping competition. The market is valued at USD 2.02 trillion in 2026 and is forecast to reach USD 6.34 trillion by 2035.

The leading biotech companies delivered strong third-quarter 2026 results. Amgen’s revenue rose 8% to USD 10.4 billion, Gilead’s product sales grew 13% to USD 8.3 billion, Regeneron’s revenue climbed 36% to USD 5.1 billion, Vertex grew 12% to USD 3.44 billion and Moderna’s revenue rose 29%. Most raised their full-year guidance.

At the same time, 2026 has become one of the busiest years for biotech dealmaking. Gilead announced four deals with about USD 12.7 billion in upfront payments, including Arcellx, Sun Pharma agreed to acquire Organon for USD 11.75 billion, GSK agreed to buy Nuvalent for USD 10.6 billion, and Regeneron expanded its antibody collaboration with Sanofi for USD 1 billion upfront and up to USD 7 billion in milestones. This release profiles the top companies, their latest performance, and what their investments mean for the market through 2035.

Market at a Glance

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Figure 1: Biotechnology Market Snapshot

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Bio-pharmacy, the part of the market made up of biotech medicines, holds 42% of revenue (about USD 848 billion in 2026, modeled on the published share), which is why the leading biotech drug companies are the focus of this release. Bioinformatics grows fastest as AI and data tools spread across research and development.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Top Companies in the Biotechnology Market

Figure 2: Top Biotechnology Companies, Q3 2026 Results

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

CompanyQ3 2026 RevenueKey Growth Drivers2026 Outlook / Strategy
AmgenUSD 10.4B (+8%)Repatha USD 1.09B (+37%), Evenity +39%, Tezspire +43%, Imdelltra +128%Revenue guide USD 38.9–39.7B; MariTide in Phase 3
Gilead SciencesUSD 8.3B; product sales +13%HIV USD 6.2B (+18%); Biktarvy USD 4.1B; Trodelvy +42%; HIV prevention nearly doubledProduct sales guide raised to USD 31.0–31.3B; four 2026 acquisitions
RegeneronUSD 5.1B (+36%)Dupixent sales USD 6.5B (+35%); EYLEA HD +62%; Libtayo +51%Expanded Sanofi antibody collaboration (Oct 2026)
VertexUSD 3.44B (+12%)Cystic fibrosis franchise; Casgevy USD 99M; Journavx USD 58MRevenue guide raised to USD 13.15–13.25B; Crinetics acquisition
ModernaUSD 1.3B (+29%)mRNA flu vaccine approved Aug 2026Revenue growth guide raised to 15–25%; cancer vaccine filing planned
BioNTechEUR 1.29BOncology pivot with BMS on pumitamigRevenue guide EUR 1.7–1.9B; seven pivotal pumitamig trials

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Three patterns stand out. First, companies with newer growth products are offsetting losses on older ones: Amgen's Prolia and Xgeva fell sharply as biosimilars launched, while Repatha, Evenity, Tezspire and Imdelltra grew strongly. Second, immunology and HIV remain major profit engines, as Dupixent's 35% growth and Gilead's 18% HIV growth show. Third, new modalities are starting to earn revenue: Vertex's gene-edited Casgevy grew almost six-fold year on year, and Moderna has added an mRNA flu vaccine.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Investments and Deals

Figure 3: Biotech Dealmaking in 2026, Selected Transactions

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Acquirer / PartnerTargetValueFocus
Gilead SciencesArcellx, Tubulis, Ouro Medicines, PepStarAbout USD 12.7B upfront (IPR&D charges USD 12.4B)Cell therapy, ADCs, immunology
Sun PharmaOrganonUSD 11.75BSpecialty and women's health portfolio
Eli LillyCentessa and other 2026 dealsAbout USD 10.8B in totalNeuroscience and other areas
GSKNuvalentUSD 10.6BLung cancer targeted therapy
PfizerInnovent (collaboration)Up to USD 10.5BADCs and multi-specific antibodies
RegeneronSanofi (expanded collaboration)USD 1B upfront; up to USD 7B in milestonesLong-acting antibodies
Merck & Co.Terns PharmaceuticalsAbout USD 6.7BChronic myeloid leukemia
BiogenApellis PharmaceuticalsUSD 5.6B upfrontImmunology and rare disease

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Large companies are spending heavily for three reasons: patent expiries on major products later this decade, strong cash flows, and the availability of late-stage assets in oncology, immunology and neuroscience. R&D budgets are also rising, with Amgen's third-quarter R&D up 11% and Regeneron guiding to more than USD 6 billion in annual R&D.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Company Developments

Figure 4: Top Biotechnology Company Moves, 2026

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

mRNA is moving into cancer and flu. Moderna and Merck reported positive Phase 3 results for intismeran autogene, an individualized mRNA cancer vaccine, which cut the risk of melanoma recurrence or death by 42% when added to Keytruda. Moderna's mRNA flu vaccine was approved by the FDA in August 2026.

What it indicates: mRNA platforms are diversifying beyond COVID-19, opening new revenue for Moderna, BioNTech and their partners.

Gene editing and cell therapy are scaling. Vertex's Casgevy earned USD 99 million in the third quarter, nearly six times the prior year, and Gilead agreed to acquire Arcellx to gain full control of its CAR-T therapy for multiple myeloma.

What it indicates: Advanced therapies are moving from launch to growth, rewarding companies with manufacturing and treatment-center networks.

Biotechs are pivoting to oncology. BioNTech is running seven pivotal trials of pumitamig, a PD-L1×VEGF-A bispecific developed with Bristol Myers Squibb, while its COVID-19 vaccine revenue declines.

What it indicates: Oncology remains the largest destination for biotech investment, and bispecifics are a key next-generation format.

Collaborations are expanding. Regeneron and Sanofi added next-generation long-acting antibodies to their collaboration in October 2026, building on Dupixent's success.

What it indicates: Proven partnerships are being extended to protect and grow immunology franchises.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Market Drivers

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Major Challenges

  • Biosimilar competition eroding older biologics, as seen with Prolia and Xgeva.
  • High R&D costs and late-stage trial failures.
  • Drug pricing pressure in the U.S. and Europe.
  • Complex manufacturing for cell and gene therapies.
  • Falling COVID-19 vaccine revenue for mRNA companies.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Emerging Opportunities

  • Bioinformatics and AI tools, the fastest-growing application.
  • Oncology bispecifics, ADCs and cancer vaccines.
  • Long-acting antibodies in immunology and respiratory disease.
  • Gene editing and CAR-T as treatment networks expand.
  • Asia Pacific partnerships and licensing.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Ecosystem

Figure 5: Biotechnology Company Ecosystem, 2026

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

The supply side includes large biotechnology companies, pharma buyers and partners, and the tools, CDMO and service providers that support research and manufacturing. The demand side includes healthcare providers, payers and governments, agriculture and industrial users, and research buyers such as universities and public agencies.

Customer and Buyer Intelligence

Target Account GroupDecision-MakersPurchase SignalsCommercial Opportunity
Pharma business developmentHead of BD, R&D HeadPatent expiries, pipeline gapsAcquisition and licensing targets
Biotech companiesCEO, CFO, CSOFunding needs, late-stage dataPartnering and exit planning
CDMOs and tools providersBD and Commercial HeadsNew modalities, capacity needsManufacturing and research supply
InvestorsPortfolio ManagersResults, deals, trial readoutsValuation and pipeline benchmarking
Governments and payersHealth Policy and HTA LeadsNew approvals, pricing reformAccess and reimbursement planning

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

How Precedence Research Supports Decision-Making

Master Dataset provides company, segment and regional data for biotechnology and adjacent markets such as the biopharmaceutical, U.S. biotechnology and red biotechnology markets. It helps teams benchmark companies by therapy area, technology and region.

Precedence Quadrant ranks biotechnology companies on revenue growth, pipeline strength, deal activity and patent exposure, helping business development teams and investors screen leaders and targets.

Interactive Intelligence Dashboard tracks quarterly results, acquisitions, approvals and trial readouts, so strategy teams can respond to competitor moves quickly.

Quality & Manufacturing Intelligence maps biologics, cell and gene therapy and mRNA manufacturing capacity, supporting sourcing and partnering decisions.

Customized Research answers specific questions, such as acquisition target screening, deal valuation benchmarks or competitor pipeline analysis.

SolutionWhat It ProvidesHow It Helps
Master DatasetCompany, segment and region data on biotechnologyBenchmarks companies and segments
Precedence QuadrantRanking on growth, pipeline and dealsScreens leaders and acquisition targets
Interactive DashboardLive tracking of results, deals and approvalsTimes BD and investment moves
Quality & Manufacturing IntelligenceBiologics, cell/gene and mRNA capacity mappingSupports manufacturing partner choices
Customized ResearchTarget screening and valuation studiesAnswers decision-specific questions

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Why Continuously Updated Intelligence Matters

Biotech company positions change with every quarter's results, deal and trial readout. Monthly updates suit business development teams tracking deals and data. Quarterly updates match company earnings, such as Amgen, Gilead and Regeneron results. Six-monthly updates align with major medical meetings and regulatory decisions, and annual updates support investors reviewing market size and company share. Precedence Research offers all four update cycles.

Strategic Outlook

  • CEOs and CXOs: the market triples to USD 6.34 trillion by 2035; leaders are using strong 2026 cash flows to buy growth before patent expiries.
  • Strategy and business development teams: 2026 deals of USD 5–13 billion set valuation benchmarks for late-stage oncology, immunology and cell therapy assets.
  • R&D leaders: bispecifics, ADCs, mRNA cancer vaccines, gene editing and long-acting antibodies are the key growth modalities.
  • Procurement and manufacturing teams: secure capacity for complex biologics and advanced therapies early.
  • Investors: biotechs with late-stage assets in oncology and immunology remain prime acquisition targets.
  • Tools and service suppliers: rising R&D budgets and the fastest growth in bioinformatics support demand.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Call to Action

To compare the top biotechnology companies and track their investments and pipelines, explore the full report or speak with a Precedence Research analyst.

Related Reports

  1. U.S. Biotechnology Market: https://www.precedenceresearch.com/us-biotechnology-market
  2. Red Biotechnology Market: https://www.precedenceresearch.com/red-biotechnology-market
  3. Biotechnology Reagents and Kits Market: https://www.precedenceresearch.com/biotechnology-reagents-and-kits-market
  4. Biotechnology and Pharmaceutical Services Outsourcing Market: https://www.precedenceresearch.com/biotechnology-and-pharmaceutical-services-outsourcing-market
  5. Biotechnology Instruments Market: https://www.precedenceresearch.com/biotechnology-instruments-market
  6. Biopharmaceutical Market: https://www.precedenceresearch.com/biopharmaceutical-market
  7. Biologics Market: https://www.precedenceresearch.com/biologics-market
  8. Gene Therapy Market: https://www.precedenceresearch.com/gene-therapy-market
  9. Bioinformatics Market: https://www.precedenceresearch.com/bioinformatics-market
  10. Drug Discovery Market: https://www.precedenceresearch.com/drug-discovery-market
  11. Personalized Medicine Market: https://www.precedenceresearch.com/personalized-medicine-market
  12. Genomics Market: https://www.precedenceresearch.com/genomics-market
  13. Proteomics Market: https://www.precedenceresearch.com/proteomics-market
  14. Microfluidics Market: https://www.precedenceresearch.com/microfluidics-market
  15. Clinical Trials Market: https://www.precedenceresearch.com/clinical-trials-market
  16. Oncology Market: https://www.precedenceresearch.com/oncology-market
  17. Immunology Market: https://www.precedenceresearch.com/immunology-market
  18. Neurology Market: https://www.precedenceresearch.com/neurology-market
  19. Biopesticides Market: https://www.precedenceresearch.com/biopesticides-market
  20. Artificial Intelligence Market: https://www.precedenceresearch.com/artificial-intelligence-market

About Precedence Research

Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, biotechnology, pharmaceuticals, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.

Our Partners

Connect With Us

  • USA: +1 804 441 9344
  • APAC: +61 485 981 310 or +91 87933 22019
  • Singapore: +65 3105 1271
  • Europe: +44 7383 092 044
  • Email: sales@precedenceresearch.com

Social Media